Investigational Therapies For Graft-versus-host Disease
There are a large number of clinical trials either ongoing or recently completed in the investigation of graft-versus-host disease treatment and prevention.
On May 17, 2012, Osiris Therapeutics announced that Canadian health regulators approved Prochymal, its drug for acute graft-versus host disease in children who have failed to respond to steroid treatment. Prochymal is the first stem cell drug to be approved for a systemic disease.
Read more about this topic: Graft-versus-host Disease
Famous quotes containing the word disease:
“War is in truth a disease in which the juices that serve health and maintenance are used for the sole purpose of nourishing something foreign, something at odds with nature.”
—Johann Wolfgang Von Goethe (1749–1832)